[The French mesothelioma network from 1998 to 2013].

Archive ouverte

Galateau-Sallé, Françoise | Gilg Soit Ilg, Anabelle | Le Stang, Nolwenn | Brochard, Patrick | Pairon, Jean-Claude | Astoul, Philippe | Frenay, Catherine | Blaizot, Gaëtane | Chamming'S, Soizick | Ducamp, Stéphane | Rousvoal, Thomas | de Quillacq, Anne | Abonnet, Véronique | Abdalsamad, Issam | Begueret, Hugues | Brambilla, Elisabeth | Capron, Frédérique | Copin, Marie-Christine | Danel, C. | de Lajartre, Anne-Yvonne | Foulet-Rogé, Armelle | Garbe, Louise | Groussard, Odile | Giusiano, S. | Hofman, Véronique | Lantuejoul, Sylvie | Piquenot, Jean-Michel | Rouquette, Isabelle | Sagan, Christine | Thivolet-Bejui, Françoise | Vignaud, Jean-Michel | Scherpereel, A. | Jaurand, Marie-Claude | Jean, D. | Hainaut, Pierre | Chérié-Challine, Laurence | Goldberg, Marcel | Luce, Danièle | Imbernon, Ellen

Edité par CCSD ; Elsevier Masson -

International audience. Mesothelioma is a rare disease less than 0.3% of cancers in France, very aggressive and resistant to the majority of conventional therapies. Asbestos exposure is nearly the only recognized cause of mesothelioma in men observed in 80% of case. In 1990, the projections based on mortality predicted a raise of incidence in mesothelioma for the next three decades. Nowadays, the diagnosis of this cancer is based on pathology, but the histological presentation frequently heterogeneous, is responsible for numerous pitfalls and major problems of early detection toward effective therapy. Facing such a diagnostic, epidemiological and medico-legal context, a national and international multidisciplinary network has been progressively set up in order to answer to epidemiological survey, translational or academic research questions. Moreover, in response to the action of the French Cancer Program (action 23.1) a network of pathologists was organized for expert pathological second opinion using a standardized procedure of certification for mesothelioma diagnosis. We describe the network organization and show the results during this last 15years period of time from 1998-2013. These results show the major impact on patient's management, and confirm the interest of this second opinion to provide accuracy of epidemiological data, quality of medico-legal acknowledgement and accuracy of clinical diagnostic for the benefit of patients. We also show the impact of these collaborative efforts for creating a high quality clinicobiological, epidemiological and therapeutic data collection for improvement of the knowledge of this dramatic disease.

Suggestions

Du même auteur

Evolution of pleural cancers and malignant pleural mesothelioma incidence in France between 1980 and 2005.

Archive ouverte | Le Stang, Nolwenn | CCSD

International audience. The evolution of pleural cancers and malignant pleural mesothelioma incidence in France between 1980 and 2005 was analysed using data derived from the French network of cancer registries (FRA...

Comprehensive Molecular and Pathologic Evaluation of Transitional Mesothelioma Assisted by Deep Learning Approach: A Multi-Institutional Study of the International Mesothelioma Panel from the MESOPATH Reference Center

Archive ouverte | Galateau Salle, Francoise | CCSD

International audience. AbstractIntroductionHistologic subtypes of malignant pleural mesothelioma are a major prognostic indicator and decision denominator for all therapeutic strategies. In an ambiguous case, a rar...

Redefining malignant pleural mesothelioma types as a continuum uncovers immune-vascular interactions

Archive ouverte | Alcala, Nicolas | CCSD

International audience

Chargement des enrichissements...